Mitsubishi Tanabe Pharma Corporation
3-2-10, Dosho-machi, Chuo-ku
Osaka
541-8505
145 articles about Mitsubishi Tanabe Pharma Corporation
-
Mitsubishi Tanabe Pharma America to Partner with ALS/MND Natural History Study Consortium to Collect Real-World Data in ALS with the Goal of Improving Patient Care
6/6/2023
Mitsubishi Tanabe Pharma America, Inc. announced they are partnering with the ALS/MND Natural History Study Consortium to collect real-world data in amyotrophic lateral sclerosis in an effort to develop a better understanding of the disease and current care practices.
-
Mitsubishi Tanabe Pharma America Announces Presentations at XXVIII World Congress on Parkinson's Disease and Related Disorders
5/12/2023
Mitsubishi Tanabe Pharma America, Inc. announced two presentations on investigational ND0612 in Parkinson's disease will be shared at the International Association of Parkinsonism and Related Disorders XXVIII World Congress on Parkinson's Disease and Related Disorders, being held in Chicago, Ill., May 13-16.
-
Between new formulations of traditional drugs nearing the market and completely novel approaches in mid-stage trials, 2023 is poised to be a pivotal year in Parkinson’s disease treatment.
-
Mitsubishi Tanabe Pharma Canada Announces New Leadership
4/3/2023
Mitsubishi Tanabe Pharma Canada announced that Andy Zylak has been appointed as the new President, effective April 1, 2023.
-
Mitsubishi Tanabe Pharma America, Inc. Announces Reorganization and Appoints New Leadership
4/3/2023
Mitsubishi Tanabe Pharma America, Inc. announced that its U.S. parent company, Mitsubishi Tanabe Pharma Holdings America, Inc. and their development entity, Mitsubishi Tanabe Pharma Development America, Inc., have merged into MTPA, effective April 1, 2023.
-
Mitsubishi Tanabe Pharma Canada Receives Engagement Letter From Pan-canadian Pharmaceutical Alliance for Radicava® Oral Suspension
3/30/2023
Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc. is pleased to announce the company has entered into negotiations with the pan-Canadian Pharmaceutical Alliance for RADICAVA® Oral Suspension for the treatment of patients with amyotrophic lateral sclerosis.
-
MITSUBISHI TANABE PHARMA CANADA ANNOUNCES RADICAVA (EDARAVONE) ORAL SUSPENSION IS NOW AVAILABLE IN CANADA FOR THE TREATMENT OF PATIENTS WITH ALS
2/10/2023
Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that RADICAVA® Oral Suspension, the oral formulation of RADICAVA® IV (edaravone), is now commercially available in Canada for the treatment of patients with amyotrophic lateral sclerosis (ALS).
-
Mitsubishi Tanabe Pharma America Announces Nearly 4,000 ALS Patients in the U.S. Have Been Treated with RADICAVA ORS® (edaravone)
1/26/2023
Mitsubishi Tanabe Pharma America, Inc. announced that nearly 4,000 people with amyotrophic lateral sclerosis have received RADICAVA ORS® since the therapy became available in the U.S. in June 2022, and 79% of patients who started treatment with RADICAVA ORS or intravenous RADICAVA® between June 1, 2022 and September 30, 2022 have continued treatment for three months or more through December.
-
Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Data at 21st Annual NEALS Meeting
11/1/2022
Mitsubishi Tanabe Pharma America, Inc. announced that six presentations on amyotrophic lateral sclerosis will be shared at the 21st Annual Northeast Amyotrophic Lateral Sclerosis Meeting, being held in Clearwater, Fla., from November 1-3.
-
EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
7/5/2022
EditForce, Inc. has entered into a License Agreement with Mitsubishi Tanabe Pharma Corporation to research, develop and commercialize potential gene therapy products for a specific target disease in the field of CNS by utilizing EditForce's proprietary PPR protein platform technology.
-
RADICAVA ORS® (edaravone) Now Available in the U.S. for the Treatment of ALS
6/15/2022
Mitsubishi Tanabe Pharma America, Inc. announced RADICAVA ORS® is now available in the United States for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that currently has no cure and can progress rapidly.
-
The U.S. Food and Drug Administration (FDA) has approved Mitsubishi Tanabe Pharma America's oral alternative to its own treatment for amyotrophic lateral sclerosis (ALS).
-
Health Canada Accepts Snds Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS
5/13/2022
Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that Health Canada has accepted the filing of a Supplement to a New Drug Submission for an investigational oral formulation of edaravone indicated for the treatment of amyotrophic lateral sclerosis.
-
Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (edaravone) for the Treatment of ALS
5/13/2022
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved RADICAVA ORS® .
-
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
-
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2022 American Academy of Neurology Annual Meeting
4/1/2022
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the 2022 American Academy of Neurology Annual Meeting.
-
The FDA released materials for review ahead of Wednesday's meeting and it appears to paint a picture of insufficient data for approval, noting it is “not exceptionally persuasive.”
-
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
1/18/2022
ADC Therapeutics SA announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications in Japan.
-
Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND
12/1/2021
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations on amyotrophic lateral sclerosis (ALS) as part of the Motor Neurone Disease Association (MNDA) 32nd International Symposium on ALS/MND, being held virtually December 7-10.
-
Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary
11/23/2021
Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA®, an infusion treatment for amyotrophic lateral sclerosis, is now reimbursed through Prince Edward Island Pharmacare under Special Authorization.